| Field | Sense | Antisense |
| siRNA chemical modification | Phosphorothioate* 2-O-Fluoro | Phosphorothioate* 2-O-Fluoro |
| siRNA modification types | 2 | 2 |
| Overall number of modifications | 7 | 6 |
| Position of modifications | 1,2,19,20 * 6,19,20 | 1,19,20 * 2,17,18 |
| Modification on sugar or base or phosphate | Sugar | Sugar |
| SMILES (Click to view structure & nomenclature) |
OCC1OCC(O)C1OP(O)(S)=O OCC1OCC(OF)C1O |
OCC1OCC(O)C1OP(O)(S)=O OCC1OCC(OF)C1O |
| siRNA Sequence | CGAAGUUUGGAUUCAUCAUUC | AUGAUGAAUCCAAACUUCGGC |
| siRNA length base-pair | 21 | 21 |
| siRNA name in paper | Mm | Mm |
| Biological activity | NA | |
| Experiment used to check activity | Northern Blot | |
| Melting temperature (oC) | NA | |
| Target gene | Human SOD1 gene | |
| siRNA concentration | 20 nM | |
| Cell or Organism used | HEK293 cells | |
| Transfection method | Lipofectamine 2000 | |
| Duration after transfection | 26 Hours | |
| Article title | Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates |
|
| Reference | 18367449 | |